(PharmaNewsWire.Com, December 01, 2020 ) According to the new market research report "In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast" published by MarketsandMarkets™.
The Global In Vivo Toxicology Market is expected to grow at a CAGR of 6.9% during the forecast period to reach to USD 6.14 Billion.
The Key Factors Who will Drives the Market Growth?
- Increasing Pharmaceutical R&D Activities - Mandatory Government Regulations for Animal Testing - Innovations in Animal Models - Exclusive In Vivo Toxicology Tests
Major Market Future Growth Opportunities:
- Increasing Research in Oncology and Personalized Medicine - Rising Demand for Humanized Animal Models
In Vivo Toxicology Market Segmentation in Detailed:
Based on product, is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models (including mice model, rat model, and other animal models). In 2017, the consumables segment is expected to account for the largest share of the global market. The large share of this segment is attributed to the increasing R&D funding for the development of new transgenic animal models, advancements in the development of genetically modified animals, and increasing pharmaceutical research for developing new drug molecules.
Based on testing type, is segmented into chronic, sub-chronic, sub-acute, and acute toxicology testing. In 2017, the chronic toxicity testing segment is expected to account for the largest share of the global market. Increasing research focused on drugs used for long-duration therapies such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives is driving the growth of the chronic toxicity testing market. However, the sub-acute toxicity testing segment is expected to register the highest CAGR of during the forecast period.
By toxicity endpoint, is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). The immunotoxicity segment is expected to account for the largest share of the global market in 2017, followed by the systemic toxicity segment. The rising demand for the development of biologics and Biosimilars is driving the growth of the immunotoxicity segment.
The major players in the global In Vivo Toxicology Market include Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), Eurofins (Luxembourg), Envigo (US), DSI (US), and The Jackson Laboratory (US).
Geographical Regions Mapped in Report:
The US is estimated to account for the largest share of the market, followed by Germany and the UK. However, China is expected to grow at the highest CAGR during the forecast period. Factors such as rising R&D funding and collaborations; initiatives by the Chinese government to promote life science research; and the strong trend of commercialization of biotechnology research are contributing to the growth of the in vivo toxicology market in China.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
